GlassScriptPhysician profile
Audra M Mccall
NPI 1306845524
$8,635.02
in general payments reported to CMS, 2019-2025
44 companies · $891 in 2025
The $891 reported for 2025 was more than what 81% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,420 · 2022: $1,937 · 2023: $1,950 · 2024: $1,437 · 2025: $891.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,278.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,278.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,071.54 | 2021-2025 | |
| Lilly USA, LLC | $905.75 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Janssen Pharmaceuticals, INC | $757.18 | 2021-2025 | Spravato, Invega Sustenna, Xarelto |
| Astrazeneca Pharmaceuticals LP | $710.89 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Pfizer INC. | $429.66 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $356.82 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $312.00 | 2021-2024 | Trintellix |
| Amgen INC. | $310.11 | 2021-2025 | Otezla, Repatha, Evenity |
| Abbott Laboratories | $307.17 | 2021-2025 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $287.89 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $277.85 | 2021-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $233.02 | 2021-2023 | Verquvo, Steglatro, Belsomra |
| Bayer Healthcare Pharmaceuticals INC. | $227.29 | 2022-2025 | |
| Teva Pharmaceuticals USA, INC. | $226.80 | 2025 | Austedo Xr, Uzedy |
| Alkermes, INC. | $204.99 | 2021 |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $185.82 | 2021-2023 | |
| Otsuka America Pharmaceutical, INC. | $168.16 | 2021-2025 | Rexulti, Abilify Maintena |
| Dexcom, INC. | $148.28 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $147.60 | 2021-2023 | Seglentis, Livalo |
| Lundbeck LLC | $143.56 | 2022-2025 | Rexulti |
| Eisai INC. | $131.26 | 2024 | |
| Almatica Pharma LLC | $116.29 | 2023-2025 | Loreev Xr, Gralise |
| Novo Nordisk INC | $106.62 | 2021-2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $105.13 | 2022-2025 | Trelegy Ellipta, Arexvy |
| Astellas Pharma US INC | $96.33 | 2021-2024 | Veozah |
| Biohaven Pharmaceuticals, INC. | $90.05 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $62.82 | 2023-2024 | Xifaxan |
| Azurity Pharmaceuticals, INC. | $53.54 | 2023-2025 | Edarbi, Horizant |
| Supernus Pharmaceuticals, INC. | $51.48 | 2022-2023 | Qelbree |
| Aimmune Therapeutics, INC. | $47.21 | 2024-2025 | Zenpep |
| Exact Sciences Corporation | $39.88 | 2024-2025 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $33.95 | 2021 | |
| Insulet Corporation | $33.55 | 2023 | Omnipod |
| Hikma Pharmaceuticals USA | $33.52 | 2024-2025 | Ryaltris |
| Avanir Pharmaceuticals, INC. | $31.01 | 2022 | |
| Arbor Pharmaceuticals, INC. | $30.93 | 2021-2022 | |
| Scilex Pharmaceuticals INC. | $24.87 | 2023 | Ztlido |
| Antares Pharma, INC. | $22.77 | 2023 | Nocdurna, Xyosted, Tlando |
| Nestle Healthcare Nutrition INC. | $22.35 | 2021 | |
| Sumitomo Pharma America, INC. | $22.33 | 2025 | Gemtesa |
| Jazz Pharmaceuticals INC. | $19.99 | 2021 | |
| Idorsia Pharmaceuticals US INC | $17.01 | 2023 | Quviviq |
| Corium, LLC | $15.44 | 2023 | Azstarys |
| Verona Pharma, INC. | $14.31 | 2025 | Ohtuvayre |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Audra Mccall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.